The Role of ICER as an Independent HTA
Who has the job of leading the evaluation of pharmaceutical value and pricing? What impact will ICER have on payer decision-making? Will manufacturers begin to adjust their list prices to reflect valuations made in ICER reports? These questions and more continue to be at the heart of discussions surrounding how to gauge value in the US healthcare system.
As manufacturers begin to be more proactive in preparation for ICER evaluations, earlier monitoring of updates to ICER value frameworks and consideration of competitor and analog ICER assessments should be a priority, particularly in relation to the development of economic models, pricing strategies, and contracting approaches. Gathering of proactive scientific advice from ICER influencers and stakeholders will better prepare manufacturers for the inevitable challenges that stem from a negative ICER assessment. Incorporation of ICER guidelines, similar to other tactics like the development of an AMCP dossier, should be considered as early as possible when developing market access strategies. Only time will tell if ICER becomes the next NICE—but for now, it is a force that is here to stay and to be reckoned with.
This webinar will explore:
- The evolution of health technology assessment in the US and possibilities for the future
- Opinions of manufacturers and US payer stakeholders on the role of ICER in the US healthcare system, as learned through a primary research study of more than 50 participants
- ICER methodologies and approaches to evaluation of clinical and health economic evidence
- Ways manufacturers can begin to more proactively prepare for an ICER assessment
Manpreet Sidhu, PhD, MBA
Divisional Principal and Head, Global Health Economics, ICON Access, Commercialisation and Communications
Dr. Sidhu has over 18 years of extensive experience health economics, including systematic reviews, economic modeling, strategic market access, and dossier development. Prior to joining ICON, Dr. Sidhu was Associate Director of Health Economics and Outcomes Research at Astellas Pharma, where she directed projects in economic modeling, strategic positioning of products, market access, and pre-launch research strategy. Before joining Astellas, she was a Health Economics Analyst at Fourth Hurdle Consulting and Abacus International. In these consulting appointments, Dr. Sidhu developed economic models, conducted literature syntheses, prepared materials for health technology assessment and managed a variety of health economics and outcomes research projects.
Nathan White, CPC
Senior Vice President, Integrated Access and Outcomes Solutions, ICON Access, Commercialisation and Communications
For more than 16 years, Mr. White has been offering clients advice on global, US, and European market access and reimbursement challenges. He began his career at Express Scripts, working in leadership, field-based, and internal operational roles in the specialty pharmacy and reimbursement support program divisions. Mr. White spent more than five years designing and implementing reimbursement operational solutions at PAREXEL Consulting and inVentiv Health, before shifting into global access consulting and value communications roles as Director of Market Access at Nucleus Global, Managing Director and Head of Market Access at eMAX Health Systems, and Global Practice Lead at ApotheCom Access Pathways and Outcomes.
Mike Pace, MBA
Senior Principal, Global Pricing and Market Access ICON Access, Commercialisation and Communications
Mr. Pace has more than 20 years of executive operating experience within global biopharmaceutical firms and digital health start-up ventures, leading commercialization and market access strategy, product development, payer account management, contracting and operations, business development, sales and leadership development functions. Prior to joining ICON, he held senior leadership roles with EMD Serono, Sanofi, and Allergan. The first U.S. outcomes-based agreements for a specialty medication (Rebif®) with a health plan (Cigna®) and with a PBM (Prime Therapeutics®) were developed and executed by Mr. Pace and his team at EMD Serono.